Compared with that in the controls, the expression of m6A regulators increased significantly (p < 0.05), including METTL14, RBM15, ZCCHC4, YTHDC1, YTHDF1, FMR1, IGF2BP2, and HNRNPA2B1, while the expression of some other m6A regulators was significantly decreased, including METTL3, METTL5, PCIF1, YTHDF2, FIF3H, and FTO in AD patients. Here, FTO is linked to Alzheimer disease.